Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 615-619

  Liu, Naifu ^a   Sheng, Xiugui ^a   Liu, Yi ^a   Zhang, Xiaoling ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

CD70; Chemotherapy resistance; Immunohistochemistry; Ovarian carcinoma; Survival

Indexed keywords

CD70 PROTEIN; CISPLATIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOLOGY; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; THERAPY RESISTANCE; TREATMENT RESPONSE;

EID: 84879028916     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S44445     Document Type: Article

References (14)

1. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev. 2001;10(2):125-129.
2. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol. 2010;3:7.
3. Boursalian TE, McEarchern JA, Law CL, Grewal IS. Targeting CD70 for human therapeutic use. Adv Exp Med Biol. 2009;647:108-119.
4. Grewal IS. CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets. 2008;12(3):341-351.
5. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J. CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol. 2005;173(6):2150-2153.
6. Ryan MC, Kostner H, Gordon KA, etal. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010;103(5):676-684.
7. Aggarwal S, He T, Fitzhugh W, etal. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer. Gynecol Oncol. 2009;115(3):430-437.
8. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4): 529-537.
9. Law CL, McEarchern JA, Grewal IS. Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):90-93.
10. Liu N, Wang X, Sheng X. The clinicopathological characteristics of 'triple-negative' epithelial ovarian cancer. J Clin Pathol. 2010;63(3): 240-243.
11. Thigpen T. A rational approach to the management of recurrent orpersistent ovarian carcinoma. Clin Obstet Gynecol. 2012;55(1): 114-130.
12. Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer. 2011;47 Suppl 3:S116-S130.
13. Oflazoglu E, Stone IJ, Gordon K, etal. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res. 2008;14(19):6171-6180.
14. McEarchern JA, Smith LM, McDonagh CF, etal. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res. 2008;14(23):7763-7772.